Humacyte Statistics
Total Valuation
Humacyte has a market cap or net worth of $219.11 million. The enterprise value is $250.59 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Humacyte has 187.27 million shares outstanding. The number of shares has increased by 27.11% in one year.
| Current Share Class | 187.27M |
| Shares Outstanding | 187.27M |
| Shares Change (YoY) | +27.11% |
| Shares Change (QoQ) | +1.85% |
| Owned by Insiders (%) | 6.13% |
| Owned by Institutions (%) | 25.52% |
| Float | 154.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 106.62 |
| Forward PS | 11.26 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 159.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.62
| Current Ratio | 1.62 |
| Quick Ratio | 0.80 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.82 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -63.44% |
| Return on Invested Capital (ROIC) | -210.61% |
| Return on Capital Employed (ROCE) | -158.79% |
| Revenue Per Employee | $7,141 |
| Profits Per Employee | -$168,041 |
| Employee Count | 220 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.68% in the last 52 weeks. The beta is 1.88, so Humacyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.88 |
| 52-Week Price Change | -73.68% |
| 50-Day Moving Average | 1.61 |
| 200-Day Moving Average | 2.13 |
| Relative Strength Index (RSI) | 34.50 |
| Average Volume (20 Days) | 4,620,959 |
Short Selling Information
The latest short interest is 32.24 million, so 17.22% of the outstanding shares have been sold short.
| Short Interest | 32.24M |
| Short Previous Month | 27.22M |
| Short % of Shares Out | 17.22% |
| Short % of Float | 20.92% |
| Short Ratio (days to cover) | 4.66 |
Income Statement
In the last 12 months, Humacyte had revenue of $1.57 million and -$36.97 million in losses. Loss per share was -$0.26.
| Revenue | 1.57M |
| Gross Profit | -73.80M |
| Operating Income | -104.69M |
| Pretax Income | -36.97M |
| Net Income | -36.97M |
| EBITDA | -97.32M |
| EBIT | -104.69M |
| Loss Per Share | -$0.26 |
Full Income StatementBalance Sheet
The company has $19.49 million in cash and $50.97 million in debt, giving a net cash position of -$31.48 million or -$0.17 per share.
| Cash & Cash Equivalents | 19.49M |
| Total Debt | 50.97M |
| Net Cash | -31.48M |
| Net Cash Per Share | -$0.17 |
| Equity (Book Value) | -4.75M |
| Book Value Per Share | -0.03 |
| Working Capital | 15.77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$105.50 million and capital expenditures -$908,000, giving a free cash flow of -$106.40 million.
| Operating Cash Flow | -105.50M |
| Capital Expenditures | -908,000 |
| Free Cash Flow | -106.40M |
| FCF Per Share | -$0.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -6,663.84% |
| Pretax Margin | -2,353.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Humacyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.11% |
| Shareholder Yield | -27.11% |
| Earnings Yield | -16.87% |
| FCF Yield | -48.56% |
Analyst Forecast
The average price target for Humacyte is $10.13, which is 765.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.13 |
| Price Target Difference | 765.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Humacyte has an Altman Z-Score of -11.62 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.62 |
| Piotroski F-Score | 2 |
